

# We link your science to clinic



## Getting ready for the clinic

Our toxicology, DMPK and CMC experts work together to get you ready for clinical execution. We make sure you have a safe starting dose, optimal dosing, and an actual drug product with correct drug labelling.

Our strategic advice will ensure you have a robust foundation for transitioning into the clinical stages of development, optimizing your drug's safety and efficacy from the outset. Working together with the LINK CTU team will minimize the risks and delays.

## Fast track into LINK's CTU

With the inhouse clinical team, the facilities and the perfect location next to the hospital, our Clinical Trial Unit (CTU) in Finland is there for enabling proof of concept, demonstrating safety, confirming efficacy, and setting the basis for further development.

With direct access to a wide network of clinical specialists in almost all therapy areas, we employ flexible study designs and a spectrum of surrogate endpoints designed to capture maximal information of the investigated compounds.

**Welcome to LINK Medical**

# Experts linking to experts



**Anita Annas**  
PhD & Principal  
Consultant  
Toxicology



**Bengt Hedin**  
MSc & Principal  
Consultant CMC



**David Dahlgren**  
PhD, Associate  
Professor &  
Principal Consultant  
DMPK



**Petri Vainio**  
MD, PhD  
CSO & Adjunct  
Professor



**Mika Scheinin**  
MD, PhD &  
Scientific Advisor

**Anita Annas**, leads our toxicology program with the aim to estimate a safe starting dose for the clinical trial. And to identify potential adverse effects and safety margins.

**Bengt Hedin**, secures the Pharmaceutical Development to deliver the right amount of active drug molecule - to the right place at the right time. Securing CMC readiness for the clinical trial.

**David Dahlgren**, provides a solid clinical pharmacology and DMPK program which is crucial for optimal dosing and safe drug labelling. David works in tight connection with the CTU team to calculate the doses using all available preclinical data.

**Petri Vainio**, leads the clinical development across our units. Petri has over 20 years of academic experience in pharmacology and drug development, a decade in the pharmaceutical industry and having served in the Finnish Medicines Agency (FIMEA) and the national ethics committee. No one is better suited to guide any project into clinical phase.

**Mika Scheinin**, is LINK Medical's Scientific Advisor in early clinical development. Having served as Professor of Clinical Pharmacology and with almost 400 scientific publications, his primary focus is receptors and neurotransmitters in the CNS. In addition Mika design and review plans for early-phase clinical trials within any therapy area.

## 100+ Phase I trials

Conduct Phase I-III at our established trial units in Helsinki and Turku, Finland.

## 30+ years of expertise

Over three decades of delivering CRO, drug development, and regulatory services - linking science to patients.

## Why LINK Medical?

Linking expertise across the entire drug development chain, we guide your innovation safely and efficiently from preclinical to post-marketing.